Factors influencing the relapse of patients with Inflammatory Bowel Disease

American Journal of Gastroenterology

Volumn 92, Issue 12 SUPPL., 1997, Pages

  Miner Jr , Philip B ^a  

^a Oklahoma Foundation for Digestive Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MESALAZINE; OLANZAPINE; PREDNISONE; SULFADIAZINE;

CIGARETTE SMOKING; CROHN DISEASE; DOSE CALCULATION; DRUG EFFECT; EOSINOPHILIA; HUMAN; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; ULCERATIVE COLITIS;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; MESALAMINE; RECURRENCE; RISK FACTORS; SMOKING;

EID: 0030806609     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Azad Khan AK, Howes DT, Piris J, et al. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis. Gut 1980;21:232-40.
2. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Gastroenterology 1995;108:A909.
3. Griffin MG, Miner PB. Review article: Refractory distal colitis: Explanations and options. Aliment Pharmacol Ther 1996;10:39-48.
4. Miner P, Daly R, Nester J, and the ROWASA® Study Group. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994;106:A736.
5. Williams CN. Role of rectal formulations: Suppositories. Scand J Gastroenterol 1990;25(suppl 172):60-2.
6. Campieri M, Paoluzi P, D'Albasio G, et al. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: A multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993;38:1843-50.
7. Campieri M, Corbelli C, Gionchetti P, et al. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992;37:1890-7.
8. Campieri M, Lanfranchi GA, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986;29:108-10.
9. van Buul MMC, Mulder CJJ, Wiltink EHH, et al. Retrograde spread of therapeutic enemas in patients with inflammatory bowel disease. Hepatogastroenterology 1989;36:199-201.
10. Chapman NJ, Brown ML, Phillips SF, et al. Distribution of mesalamine enemas in patients with active distal ulcerative colitis. Mayo Clin Proc 1992;67:245-8.
11. Vitti RA, Meyers F, Knight LC, et al. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. Dig Dis Sci 1989;34:1792-7.
12. Adler RD. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982;307:315 (letter).
13. Ruppin H, Domschke S. Acute ulcerative colitis: A rare complication of sulfasalazine therapy. Hepatogastroenterology 1984;31:192-3.
14. Schwartz AG, Targan SR, Saxon A, et al. Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med 1982;306:409-12.
15. Werlin SL, Grand RJ. Bloody diarrhea: A new complication of sulfasalazine. J Pediatr 1978;92:450-1.
16. Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate-induced exacerbation of ulcerative colitis. Gut 1987;28:613-5.
17. Shanahan F, Targan S. Sulfasalazine and salicylate-induced exacerbation of ulcerative colitis. N Engl J Med 1987;317:455 (letter).
18. Sturgeon JB, Bhatia P, Hermens D, et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology 1995;108:1889-93.
19. Spry CJF, Tai P-C, Barkans J. Tissue localization of human eosinophil cationic proteins in allergic diseases. Int Arch Allergy Appl Immunol 1985;77:252-4.
20. Goldman H, Proujansky R. Allergic proctitis and gastroenteritis in children: Clinical and mucosal biopsy features in 53 cases. Am Surg Pathol 1986;10:75-86.
21. Sarin SK, Malhotra V, Sen Gupta S, et al. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis: A prospective controlled study. Dig Dis Sci 1987;32:363-7.
22. Dubucquoi S, Janin A, Klein O, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995;37:242-6.
23. Raab Y, Sundberg C, Hällgren R, et al. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol 1995;90:614-20.
24. Metwali A, Blum AM, Ferraris L, et al. Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994;52:69-78.
25. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut 1990;31:179-83.
26. Tysk C, Järnerot G. Seasonal variation in exacerbations of ulcerative colitis. Scand J Gastroenterol 1993;28:95-6.
27. Kangro HO, Chong SKF, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98:549-53.
28. Hermens DJ, Miner PB Jr. Exacerbation of ulcerative colitis. Gastroenterology 1991;101:254-62.
29. Biddle WL, Harms JL, Greenberger NJ, et al. Evaluation of antibiotic-associated diarrhea with a latex agglutination test and cell culture cytotoxicity assay for Clostridium difficile. Am J Gastroenterol 1989; 84:379-82.
30. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 1980;141:92-7.
31. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107:513-6.
32. Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
33. Somasundaram S, Macpherson AJ, Hayllar J, et al. Enterocyte mitochondrial damage due to NSAID in the rat. Gut 1992;33(suppl):S5.
34. Roediger WEW, Millard S. Selective inhibition of fatty acid oxidation in colonocytes by ibuprofen: A cause of colitis? Gut 1995;36:55-9.
35. Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2:1171-4.
36. Oriishi T, Sata M, Toyonaga A, et al. Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 1995;36:891-6.
37. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicyclic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395-403.
38. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108:1566-81.
39. Harries AD, Jones L, Heatley RV, et al. Smoking habits and inflammatory bowel disease: Effect on nutrition. Br Med J 1982;248:1161 (abstract).
40. Pullan RD, Rhodes J, Subramanian G, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811-5.
41. Thomas GA, Rhodes J, Mani V, et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995;332:988-92.